Influence of Pathophysiologic Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes

Author:

Collet Carlos1ORCID,Munhoz Daniel12ORCID,Mizukami Takuya13ORCID,Sonck Jeroen1ORCID,Matsuo Hitoshi4ORCID,Shinke Toshiro5ORCID,Ando Hirohiko6,Ko Brian7ORCID,Biscaglia Simone8,Rivero Fernando9ORCID,Engstrøm Thomas10ORCID,Arslani Ketina10,Leone Antonio Maria111213ORCID,van Nunen Lokien X.14ORCID,Fearon William F.15ORCID,Christiansen Evald Høj16ORCID,Fournier Stephane17,Desta Liyew18,Yong Andy19ORCID,Adjedj Julien20,Escaned Javier21ORCID,Nakayama Masafumi22ORCID,Eftekhari Ashkan23,Zimmermann Frederik M.24,Sakai Koshiro15ORCID,Storozhenko Tatyana125ORCID,da Costa Bruno R.2627ORCID,Campo Gianluca8ORCID,West Nick E.J.28ORCID,De Potter Tom1ORCID,Heggermont Ward1ORCID,Buytaert Dimitri1,Bartunek Jozef1ORCID,Berry Colin2930ORCID,Collison Damien2930ORCID,Johnson Thomas31,Amano Tetsuya6ORCID,Perera Divaka32ORCID,Jeremias Allen33ORCID,Ali Ziad33ORCID,Pijls Nico H.J.24ORCID,De Bruyne Bernard117ORCID,Johnson Nils P.34ORCID

Affiliation:

1. Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.).

2. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy (D.M.).

3. Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan (T.M.).

4. Department of Cardiovascular Medicine, Gifu Heart Center, Japan (H.M.).

5. Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan (T. Shinke, K.S.).

6. Department of Cardiology, Aichi Medical University, Japan (H.A., T.A.).

7. Monash Cardiovascular Research Centre, Monash University and Monash Heart, Monash Health, Clayton, Victoria, Australia (B.K.).

8. Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Italy (S.B., G.C.).

9. Cardiac Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain (F.R.).

10. Rigshospitalet, University of Copenhagen, Denmark (T.E., K.A.).

11. Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy (A.M.L.).

12. IRCCS, Catholic University School of Medicine, Largo A. Gemelli, Rome, Italy (A.M.L.).

13. Center of Excellence in Cardiovascular Diagnostics and Therapeutic, Ospedale Fabenefratelli Isola Tiberina Gemelli Isola, Rome, Italy (A.M.L.).

14. Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands (L.X.v.N.).

15. Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine and VA Palo Alto Health Care System, Palo Alto, CA (W.F.F.).

16. Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark (E.H.C.).

17. Department of Cardiology, University Hospital of Lausanne, Switzerland (S.F., B.D.B.).

18. Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden (L.D.).

19. Concord Repatriation General Hospital, University of Sydney, New South Wales, Australia (A.Y.).

20. Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France (J.A.).

21. Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Madrid, Spain (J.E.).

22. Department of Cardiology, Tokyo D Tower Hospital, Japan (M.N.).

23. Department of Cardiology, Aalborg University Hospital, Denmark (A.E.).

24. Department of Cardiology, Catharina Hospital Eindhoven, the Netherlands (F.M.Z., N.H.J.P.).

25. Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine (T. Storozhenko).

26. Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK (B.R.d.C.).

27. Clinical Epidemiology & Health Care Research, Institute of Health Policy and Management Evaluation, University of Toronto, Canada (B.R.d.C.).

28. Abbott Vascular, Santa Clara, CA (N.E.J.W.).

29. School of Cardiovascular and Metabolic Health, University of Glasgow, UK (C.B., D.C.).

30. NHS Golden Jubilee Hospital, Clydebank, UK (C.B., D.C.).

31. University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK (T.J.).

32. School of Cardiovascular Medicine and Sciences, St Thomas’ Hospital Campus, King’s College London, UK (D.P.).

33. St Francis Hospital and Heart Center, Roslyn, NY (A.J., Z.A.).

34. Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX (N.P.J.).

Abstract

BACKGROUND: Diffuse coronary artery disease affects the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiologic coronary artery disease patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularization and procedural outcomes. METHODS: This prospective, investigator-initiated, single-arm, multicenter study enrolled patients with at least one epicardial lesion with an FFR ≤0.80 scheduled for PCI. Manual FFR pullbacks were used to calculate PPG. The primary outcome of optimal revascularization was defined as an FFR ≥0.88 after PCI. RESULTS: A total of 993 patients with 1044 vessels were included. The mean FFR was 0.68±0.12, PPG 0.62±0.17, and the post-PCI FFR was 0.87±0.07. PPG was significantly correlated with the change in FFR after PCI (r=0.65 [95% CI, 0.61–0.69]; P <0.001) and demonstrated excellent predictive capacity for optimal revascularization (area under the receiver operating characteristic curve, 0.82 [95% CI, 0.79–0.84]; P <0.001). FFR alone did not predict revascularization outcomes (area under the receiver operating characteristic curve, 0.54 [95% CI, 0.50–0.57]). PPG influenced treatment decisions in 14% of patients, redirecting them from PCI to alternative treatment modalities. Periprocedural myocardial infarction occurred more frequently in patients with low PPG (<0.62) compared with those with focal disease (odds ratio, 1.71 [95% CI, 1.00–2.97]). CONCLUSIONS: Pathophysiologic coronary artery disease patterns distinctly affect the safety and effectiveness of PCI. PPG showed an excellent predictive capacity for optimal revascularization and demonstrated added value compared with an FFR measurement. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04789317.

Funder

Abbott - Abbott Vascular

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3